As the U.S. stock market navigates a period of volatility, with major indices like the Nasdaq retreating from record highs amid anticipation of key economic data releases, investors are closely watching for signs that could influence future monetary policy decisions. In this climate, high-growth tech stocks in the United States remain a focal point for many investors seeking opportunities in sectors poised to benefit from technological advancements and innovation.
Name
Revenue Growth
Earnings Growth
Growth Rating
ACADIA Pharmaceuticals
10.87%
25.66%
★★★★★☆
ADMA Biologics
20.61%
23.25%
★★★★★☆
Palantir Technologies
25.38%
32.02%
★★★★★★
Circle Internet Group
30.80%
60.66%
★★★★★★
Workday
11.38%
29.97%
★★★★★☆
Mereo BioPharma Group
51.11%
57.42%
★★★★★★
OS Therapies
38.35%
16.51%
★★★★★☆
Vanda Pharmaceuticals
22.66%
57.41%
★★★★★☆
Gorilla Technology Group
27.85%
105.48%
★★★★★☆
Aldeyra Therapeutics
49.14%
72.47%
★★★★★☆
Click here to see the full list of 66 stocks from our US High Growth Tech and AI Stocks screener.
Underneath we present a selection of stocks filtered out by our screen.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Protagonist Therapeutics, Inc. is a biopharmaceutical company focused on developing peptide therapeutics for hematology and blood disorders, as well as inflammatory and immunomodulatory diseases, with a market cap of $3.18 billion.
Operations: Protagonist Therapeutics generates revenue primarily from its biotechnology segment, specifically focusing on startups, amounting to $209.18 million. The company’s efforts are concentrated on developing peptide therapeutics for specific medical conditions.
Protagonist Therapeutics, despite a challenging year with a net loss widening to $46.43 million from a prior net income of $176.72 million, continues to invest in groundbreaking research, particularly in the treatment of polycythemia vera as demonstrated by their successful Phase 3 VERIFY study. This focus on specialized biotech solutions underscores its potential in an industry where innovation directly correlates with market success. The company’s significant R&D investments are aimed at pioneering treatments that address unmet medical needs, indicating a strategic push towards securing a strong position within the biotech sector. While recent financial figures show volatility, Protagonist’s aggressive growth strategy in R&D could set them apart if their pipeline products achieve commercial success.
Story Continues